"ALMS has experienced a massive price spike driven by breaking positive news: successful Phase 3 psoriasis trial results announced on January 6, 2026, leading to a 126% surge that day, followed by an upsized public offering priced at $17 per share, set to close on January 9. This is in a hot biotechnology sector (+3.2%) and a detected bull market regime, where longs are favored. Despite RSI being overbought at 78.4, the strong fundamental catalyst overrides technical concerns, with price well above SMA20 and SMA50, supporting continued upward momentum towards resistance at $22.30. As a day trading opportunity, entering long pre-market captures the momentum from the news, with a favorable risk/reward setup."